The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Immune checkpoint blockade for glioblastoma: Preclinical activity of single agent and combinatorial therapy.
David A. Reardon
Consultant or Advisory Role - Amgen; EMD Serono; Merck; Momenta Pharmaceuticals; Novartis; Roche/Genentech; Stemline Therapeutics
Honoraria - Merck; Roche/Genentech
Prafulla C. Gokhale
No relevant relationships to disclose
F. Stephen Hodi
Consultant or Advisory Role - Bristol-Myers Squibb (U); Merck (U); Roche/Genentech (U)
Keith L. Ligon
No relevant relationships to disclose
Xiaoyun Liao
No relevant relationships to disclose
Scott J. Rodig
No relevant relationships to disclose
Jun Zhou
No relevant relationships to disclose
Lei Qin
No relevant relationships to disclose
Kristen Jones
No relevant relationships to disclose
Amy Sauer
No relevant relationships to disclose
Nancy E. Kohl
No relevant relationships to disclose
Glenn Dranoff
Consultant or Advisory Role - Novartis
Honoraria - Axon Advisors; Lilly; Merck; Roche/Genentech
Research Funding - Bristol-Myers Squibb (I); Novartis
Gordon James Freeman
Consultant or Advisory Role - Costim Pharmaceuticals (I); Costim Pharmaceuticals
Stock Ownership - Costim Pharmaceuticals